Quantitative Analysis of [11C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain
Petrulli JR, Sullivan JM, Zheng MQ, Bennett DC, Charest J, Huang Y, Morris ED, Contessa JN. Quantitative Analysis of [11C]-Erlotinib PET Demonstrates Specific Binding for Activating Mutations of the EGFR Kinase Domain. Neoplasia 2013, 15: 1347-1353. PMID: 24403856, PMCID: PMC3884525, DOI: 10.1593/neo.131666.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarbon RadioisotopesCatalytic DomainCell Line, TumorDrug Evaluation, PreclinicalErbB ReceptorsErlotinib HydrochlorideGene ExpressionHumansMiceMice, NudeMutation, MissenseNeoplasm TransplantationPhosphorylationPositron-Emission TomographyProtein BindingProtein Processing, Post-TranslationalQuinazolinesRadiopharmaceuticalsConceptsNon-small cell lung cancerEpidermal growth factor receptorPositron emission tomographyMutant non-small cell lung cancerNovel clinical methodologyCell lung cancerMutations of EGFREGFR mutation statusDomain mutationsHuman cancer xenograftsKinase domain mutationsConstitutive EGFR phosphorylationMultiple tumor typesPET scan analysisMolecular imaging approachesExtracellular domain mutationsWild-type epidermal growth factor receptorSimplified reference tissue modelGrowth factor receptorReference tissue modelNSCLC xenograftsLung cancerCancer xenograftsMalignant gliomasClinical utility